The European study is expected to enroll 40 newly diagnosed AML patients. ・Enrollment at U.S. sites is planned to begin in the first quarter of 2026, with European enrollment anticipated in the second ...

Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...

NOSTRAND ROBERT L VAN, a director at $SLS, bought 10,000 shares of the company on 06-12-2025 for an estimated $14,800. This trade was reported by Quiver Quantitative ...

$SLS insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...

Seelos Therapeutics (NASDAQ:SEEL) shares are trading higher Tuesday after the company signed a material transfer agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA) to supply ...

SELLAS Life Sciences Group ( (SLS)) just unveiled an update. Subsequent to December 31, 2025, SELLAS Life Sciences Group, a biopharmaceutical company, received approximately $26.5 million in cash ...

SELLAS Life Sciences Gr (NASDAQ:SLS) Stock, Option Chain Option chain shows key data for SELLAS Life Sciences Gr's stock options at various strike prices and expiration dates. Traders use this ...

SELLAS Life Sciences' value hinges on the pivotal REGAL phase 3 trial in AML, with interim results showing promise, but final outcomes still unknown. Despite encouraging data, I remain highly cautious ...